Advancing a Pipeline of Targeted Precision Oncology Therapeutics

Kinase inhibition is a proven approach to fighting cancer, and for nearly two decades has addressed an increasing number of oncology indications. At Kinate, we employ a consistent, systematic approach to identify kinases that drive difficult-to-treat, genomically-defined diseases.

Through this approach, we aim to develop kinase inhibitor product candidates with therapeutic windows that provide durable and meaningful clinical responses to benefit patients in three patient populations:

    1. those with cancers that harbor known oncogenic drivers with no currently available targeted therapies;
    2. those with genomically well-characterized tumors that have intrinsic resistance to currently available treatments; and
    3. those whose tumors have acquired resistance over the course of therapy to currently available treatments.

By focusing on these three well-characterized patient populations, we believe that we will have a more efficient development path with a greater likelihood of success. Due to advancements in genomic profiling and relationships with our collaborating precision medicine cancer centers and leading research institutions, we have established and continue to develop a deep expertise and understanding of specific oncogenic drivers.

Our lead programs include candidates in preclinical development for cancers that are driven by specific oncogenic alterations in either the BRAF kinase gene, or in the FGFR2 and FGFR3 kinase genes. We are also advancing a number of other small molecule development programs, including a Cyclin-Dependent Kinase 12 (CDK12) inhibitor. To help advance these programs, Kinnate is working with leaders at experienced precision medicine cancer centers including Massachusetts General Hospital Cancer Center and the UC San Diego Moores Cancer Center.

“We look at cancer as having individual fingerprints or vulnerabilities and design programs that can penetrate those weak spots.”

– Eric Murphy, PhD, CSO & Co-Founder of Kinnate

A Focused Pipeline Portfolio

We have developed a proprietary kinase inhibitor portfolio of small molecule candidates advancing towards clinical studies.

No results found.

“Kinnate’s targeted approach will fill a significant unmet need and bring better precision therapies to cancer patients. As an SAB member, I look forward to working closely with the Kinnate team to advance its pipeline of innovative kinase inhibitors.”

– Ezra Cohen, MD, FRCPSC, FASCO, Kinnate SAB Member